



Software for  
Business Intelligence

**BizInt Smart Charts**



**BIZINT**

# Smart Chat:

## A new look for BizInt Smart Charts

*Diane Webb, John Willmore, Matt Eberle, and Bertha Adamson*

*26 March 2025*

[www.bizint.com](http://www.bizint.com)

## *Introducing Patsnap Synapse*

- Drug Development Suite version 5.8.3 introduces support for drug profiles from Patsnap Synapse
- Use the BizInt (BRD) export
- We are starting our first “Surfing the Pipeline” evaluation of Synapse in conjunction with other sources

# Introducing Patsnap Synapse

Unsaved1

Synapse Drugs: Takeda Synapse 3-7-25

Drug Name	Developer	Highest Phase (Normalized)	Indication Phase (Normalized)		Indication	Mechanism of Action	Update Date
			Indication	Phase			
1 Apadamtase alfa /Cinaxadamtase alfa	The Chemo-Sero-Therapeutic Research Institute	Launched	Congenital Thrombotic Thrombocytopenic Purpura	Launched	Congenital Thrombotic Thrombocytopenic Purpura Thrombotic Thrombocytopenic Purpura, Acquired Anemia, Sickle Cell [Purpura, Thrombotic Thrombocytopenic]	vWFCP modulators Enzyme replacements	
			Thrombotic Thrombocytopenic Purpura, Acquired	Phase 2			
			Anemia, Sickle Cell	Phase 1			
			[Purpura, Thrombotic Thrombocytopenic]	Phase 1			
2 Dengue vaccine tetravalent(Takeda)	Takeda Pharmaceutical Co., Ltd.	Launched	Dengue [Hepatitis A]	Launched	Dengue	Immunostimulants	
			[Yellow Fever]	Phase 3			
				Phase 3			
3 Pacritinib	CTI BioPharma Corp.	Launched	Primary Myelofibrosis	Launched	Primary Myelofibrosis Thrombocytopenia Post-essential thrombocythemia myelofibrosis Post-polycythemia vera myelofibrosis VEXAS syndrome [COVID-19] [Refractory Colorectal Carcinoma] [Myeloproliferative Disorders] [Leukemia] [Myelodysplastic Syndromes] [Lymphoplasmacytic Lymphoma] [Mantle Cell Lymphoma]	ALK2 inhibitors CSF-1R antagonists FLT3 inhibitors IRAK1 antagonists JAK2 inhibitors	
			Thrombocytopenia	Launched			
			Post-essential thrombocythemia myelofibrosis	Phase 3			
			Post-polycythemia vera myelofibrosis	Phase 3			
			VEXAS syndrome	Phase 2			
			[COVID-19]	Phase 2			
			[Refractory Colorectal Carcinoma]	Phase 2			
			[Myeloproliferative Disorders]	Phase 2			
			[Leukemia]	Phase 2			
			[Myelodysplastic Syndromes]	Phase 2			
[Lymphoplasmacytic Lymphoma]	Phase 2						
[Mantle Cell Lymphoma]	Phase 2						

# Introducing Patsnap Synapse

- A key difference is “inactive indications”
- Displayed in square braces in lists and tables
- Indication Phase (Normalized) table will only show an indication once, showing development phase in active development (if available)

Indication Phase (Normalized)	
Indication	Phase
Congenital Thrombotic Thrombocytopenic Purpura	Launched
Thrombotic Thrombocytopenic Purpura, Acquired	Phase 2
Anemia, Sickle Cell	Phase 1
[Purpura, Thrombotic Thrombocytopenic]	Phase 1
Dengue	Launched
[Hepatitis A]	Phase 3
[Yellow Fever]	Phase 3

# Patsnap Bio

- IP sequences “first look” in BizInt Smart Charts for Patents 5.9.3
- There is an issue with SEQ ID NO which the Patsnap team are working on resolving
- There is a chance we will add a new release (version 5.9.4) when the issue is resolved

SEQ ID NO	Sequence ID
SEQ ID. 737, 322, 596, 369, 690, 228, 275, 643	
SEQ ID. 378, 605, 652, 331, 699, 237, 284	
746	US11015201-0746
SEQ ID. 780, 874, 827, 921	
SEQ ID. 930, 789, 836, 883	
SEQ ID. 803, 850, 897	

# A cleaner new appearance

PatSnap BIO: zilbesiran\_sequences

	Patent Number	Common Family	Patent Date	
1 a	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
1 b	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
1 c	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
1 d	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
1 e	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
1 f	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
1 g	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof
1 h	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof

PatSnap BIO: zilbesiran\_sequences

	Patent Number	Common Family	Patent Date	Title	Patent Assignee	Priority Date
1 a	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14
1 b	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14
1 c	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14
1 d	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14
1 e	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14
1 f	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14
1 g	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14
1 h	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14

# Using color to identify the product

- BizInt Smart Charts uses blue column headings

PatSnap BIO: zilbesiran\_sequences

	Patent Number	Patent Date	Title	Patent Assignee	Priority Date	SEQ ID NO
5	US 11015201 B2	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 737, 322, 596, 369, 690, 228, 275, 643
6	US 11015201 B2	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 378, 605, 652, 331, 699, 237, 284
7	US 11015201 B2	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 555, 11

- Smart Data Integrator uses tan

PatSnap BIO: zilbesiran\_sequences

	Patent Number	Common Family	Patent Date	Title	Patent Assignee	Priority Date	SEQ ID NO
1 a	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 957, 713, 951, 345, 619, 9, 251, 298
1 b	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 529, 941, 12, 947, 114, 67, 161, 948, 946, 482, 435, 10
1 c	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 555, 11

# Using color to identify the product

- Patents data uses teal for selection

PatSnap BIO: zilbesiran\_sequences

	Patent Number	Common Family	Patent Date	Title	Patent Assignee	Priority Date	SEQ ID NO
1 a	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 957, 713, 951, 345, 619, 9, 251, 298
1 b	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 529, 941, 12, 947, 114, 67, 161, 948, 946, 482, 435, 10
1 c	US 11015201 B2	US 11015201	2021-05-25	Angiotensinogen (AGT) iRNA compositions and methods of use thereof	ALNYLAM PHARMA INC	2018-05-14	SEQ ID. 556, 11

- Drug Development Suite uses plum for selection

Synapse Drugs: Takeda Synapse 3-7-25

	Drug Name	Common Drug Name	Developer	Highest Phase (Normalized)	Indication Phase (Normalized)		Indication
					Indication	Phase	
1	Apadamtase alfa /Cinaxadamtase alfa	Apadamtase alfa /Cinaxadamtase alfa	The Chemo-Sero-Therapeutic Research Institute	Launched	Congenital Thrombotic Thrombocytopenic Purpura Thrombotic Thrombocytopenic Purpura, Acquired Anemia, Sickle Cell [Purpura, Thrombotic Thrombocytopenic]	Launched Phase 2 Phase 1 Phase 1	Congenital Thrombotic Thrombocytopenic Purpura Thrombotic Thrombocytopenic Purpura, Acquired Anemia, Sickle Cell
2	Dengue vaccine tetravalent(Takeda)	Dengue vaccine tetravalent	Takeda Pharmaceutical Co., Ltd.	Launched	Dengue [Hepatitis A] [Yellow Fever]	Launched Phase 3 Phase 3	Dengue



## *Beyond good looks*

- Selecting cells, rows, or columns works better now
- BizInt Smart Charts doesn't lose track of the selection
- Fixed issues with cell editing
- Laid the groundwork for new features

## *Issues with Orbit exports*

- The BizInt export on Orbit.com is in a degraded state
- No hit highlights, no labeling of abstract/claims source
- Use the XML export when possible

## *Database Changes*

- STN - support sequence alignments for most (all?) search algorithms; add missing fields
- GenomeQuest - added support for Discovery Browser annotations
- PatBase - family notes display sensibly for publication level data
- Pharmaprojects - fix issues with originator in the Company Status table

## *On the horizon*

- We are working towards version 6.0 later this spring
- Improved Combine / Update workflow
- A few more fixes for the Smart Data Integrator (most importantly row shading)
- File format changes to support new capabilities
- VP-SCE Version 16.1 is in final testing



Software for  
Business Intelligence

**BizInt Smart Charts**

**BIZINT**

THE JOURNEY CONTINUES...

*Questions?*

*Requests?*

[support@bizint.com](mailto:support@bizint.com)